Background

COVID-19 is considered the most critical health pandemic of 21st century. Due to extremely high transmission rate, people are more susceptible to viral infection. COVID-19 patients having chronic type-2 asthma prevails a major risk as it may aggravate the disease and morbidities.

Objective

The present review mainly focuses on correlating the influence of COVID-19 in type-2 asthmatic patients. Besides, it delineates the treatment measures and drugs that can be used to manage mild, moderate, and severe symptoms of COVID-19 in asthmatic patients, thus preventing any exacerbation.

Methods

An in-depth research was carried out from different peer-reviewed articles till September 2020 from several renowned databases like PubMed, Frontier, MEDLINE, and related websites like WHO, CDC, MOHFW, and the information was analysed and written in a simplified manner.

Results

The progressive results were quite conflicting as severe cases of COVID-19 shows an increase in the level of several cytokines that can augment inflammation to the bronchial tracts, worsening the asthma attacks. Contradicting to this, certain findings reveal the decrease in the severity of COVID-19 due to the elevation of T-cells in type-2 asthmatic patients, as prominent reduction of T-cell is seen in most of the COVID-19 positive patients. This helps to counteract the balance of immune responses and hence ameliorate the disease progression.

Conclusion

Asthmatic patients must remain cautious during the COVID-19 pandemic by maintaining all the precautions to stay safe due to limited research data. Future strategies should include a better understanding of asthmatic exacerbation and its relation to COVID-19.

中文翻译：

---

COVID-19 对 2 型哮喘的影响及其管理综述

背景

COVID-19 被认为是 21 世纪最严重的健康大流行病。由于极高的传播率，人们更容易受到病毒感染。患有慢性 2 型哮喘的 COVID-19 患者是一个主要风险，因为它可能会加重疾病和发病率。

客观的

本综述主要侧重于关联 COVID-19 对 2 型哮喘患者的影响。此外，它描述了可用于控制哮喘患者 COVID-19 的轻度、中度和重度症状的治疗措施和药物，从而防止任何恶化。

方法

对 PubMed、Frontier、MEDLINE 等多个知名数据库以及 WHO、CDC、MOHFW 等相关网站截至 2020 年 9 月的不同同行评议文章进行了深入研究，并以简化的方式分析和编写信息。

结果

由于 COVID-19 的严重病例显示几种细胞因子水平升高，这些进展性结果非常矛盾，这些细胞因子可以增加支气管炎症，加重哮喘发作。与此相反，某些研究结果表明，由于 2 型哮喘患者的 T 细胞升高，COVID-19 的严重程度有所降低，因为大多数 COVID-19 阳性患者的 T 细胞显着减少。这有助于抵消免疫反应的平衡，从而改善疾病进展。

结论

由于研究数据有限，哮喘患者必须在 COVID-19 大流行期间保持谨慎，采取所有预防措施以确保安全。未来的策略应包括更好地了解哮喘发作及其与 COVID-19 的关系。